Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: A randomized, controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 8, 2012, Pages 2809-2817

  Mostaghel, Elahe A ^a,b   Lin, Daniel W ^a,c   Amory, John K ^b   Wright, Jonathan L ^a,c   Marck, Brett T ^d   Nelson, Peter S ^a,b   Matsumoto, Alvin M ^b,d   Bremner, William J ^b   Page, Stephanie T ^b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; DUTASTERIDE; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; PLACEBO; TESTOSTERONE;

ARTICLE; CONTROLLED STUDY; DRUG ERUPTION; DRUG INDUCED HEADACHE; EPITHELIUM CELL; FKBP5 GENE; FOLH1 GENE; GENE; GENE EXPRESSION; HORMONAL CONTRACEPTION; HUMAN; HUMAN TISSUE; MALE; NKX3.1 GENE; NORMAL HUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PSA GENE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TESTOSTERONE BLOOD LEVEL; TMPRSS2 GENE; UNIVERSITY HOSPITAL;

ADULT; ANDROGENS; CONTRACEPTION; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PROSTATE; RECEPTORS, ANDROGEN; SINGLE-BLIND METHOD;

EID: 84864808462     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1536     Document Type: Article

References (34)

1. Amory JK, Page ST, Bremner WJ 2006 Recent advances in male hormonal contraception. Nat Clin Pract Endocrinol Metab 2:32-41
2. Brady BM, Amory JK, Perheentupa A, Zitzmann M, Hay CJ, Apter D, Anderson RA, Bremner WJ, Pollanen P, Nieschlag E, Wu FC, Kersemaekers WM 2006 A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive. Hum Reprod 21:285-294 (Pubitemid 41794323)
3. Turner L, Conway AJ, Jimenez M, Liu PY, Forbes E, McLachlan RI, Handelsman DJ 2003 Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab 88:4659-4667 (Pubitemid 37357508)
4. Page ST, Amory JK, Anawalt BD, Irwig MS, Brockenbrough AT, Matsumoto AM, Bremner WJ 2006 Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab 91:4374-4380 (Pubitemid 44833412)
5. Amory JK, Bremner WJ 2005 Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. J Clin Endocrinol Metab 90:2610-2617 (Pubitemid 40686298)
6. Amory JK, Page ST, Bremner WJ 2006 Oral testosterone in oil: pharmacokinetic effects of 5α reduction by finasteride or dutasteride and food intake in men. J Androl 27:72-78 (Pubitemid 43106737)
7. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL 2004 Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89:503-510 (Pubitemid 38269849)
8. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman Jr CA 2003 The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215-224 (Pubitemid 36859473)
9. Burkman R, Schlesselman JJ, Zieman M 2004 Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 190:S5-S22 (Pubitemid 38561489)
10. George FW, Wilson JD 1994 The physiology of reproduction. New York: Raven Press, Ltd.
11. Geller J 1990 Effect of finasteride, a 5α-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab 71:1552-1555 (Pubitemid 120032774)
12. Geller J, Albert J 1987 Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH). Urol Res 15:151-153 (Pubitemid 17116900)
13. Mohler JL, Gregory CW, Ford 3rd OH, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS 2004 The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440-448 (Pubitemid 38173980)
14. Forti G, Salerno R, Moneti G, Zoppi S, Fiorelli G, Marinoni T, Natali A, Costantini A, Serio M, Martini L, et al. 1989 Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content. J Clin Endocrinol Metab 68:461-468 (Pubitemid 19052893)
15. Habib FK, Ross M, Tate R, Chisholm GD 1997 Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia. Clin Endocrinol (Oxf) 46:137-144 (Pubitemid 27122158)
16. Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ 2006 Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 91:3850-3856 (Pubitemid 44536854)
17. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS 2007 Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67:5033-5041 (Pubitemid 46910214)
18. Page ST, Lin DW, Mostaghel EA, Marck BT, Wright JL, Wu J, Amory JK, Nelson PS, Matsumoto AM 2011 Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial. J Clin Endocrinol Metab 96:430-437
19. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT 1992 The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148:1549-1557; discussion 1564
20. Roth MY, Page ST, Lin K, Anawalt BD, Matsumoto AM, Snyder CN, Marck BT, Bremner WJ, Amory JK 2010 Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency. J Clin Endocrinol Metab 95:3806-3813
21. Kalhorn TF, Page ST, Howald WN, Mostaghel EA, Nelson PS 2007 Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrum 21:3200-3206 (Pubitemid 47441781)
22. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS 2008 Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration- resistant tumor growth. Cancer Res 68:4447-4454
23. Mostaghel EA, Geng L, Holcomb I, Coleman IM, Lucas J, True LD, Nelson PS 2010 Variability in the androgen response of prostate epithelium to 5α-reductase inhibition: implications for prostate cancer chemoprevention. Cancer Res 70:1286-1295
24. Tusher VG, Tibshirani R, Chu G 2001 Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121 (Pubitemid 32397092)
25. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB 2011 Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variant. Clin Cancer Res 17:5913-5925
26. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS 2006 Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 296:2351-2361 (Pubitemid 44749363)
27. Matthiesson KL, McLachlan RI 2006 Male hormonal contraception: concept proven, product in sight? Hum Reprod Update 12:463-482 (Pubitemid 43923418)
28. Lax ER, Baumann P, Schriefers H 1984 Changes in the activities of microsomal enzymes involved in hepatic steroid metabolism in the rat after administration of androgenic, estrogenic, progestational, anabolic and catatoxic steroids. Biochem Pharmacol 33:1235-1241 (Pubitemid 14131874)
29. Africander D, Verhoog N, Hapgood JP 2011 Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 76:636-652
30. Wilson JD 2001 The role of 5α-reduction in steroid hormone physiology. Reprod Fertil Dev 13:673-678 (Pubitemid 34240215)
31. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, Group RS 2010 Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192-1202
32. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S 2005 Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60:1451-1457 (Pubitemid 41798454)
33. Roddam AW, Allen NE, Appleby P, Key TJ 2008 Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100:170-183 (Pubitemid 351480553)
34. Luu-The V, Bélanger A, Labrie F 2008 Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 22:207-221 (Pubitemid 351611954)